Annovis Bio, Inc. (ANVS)
NYSE: ANVS · Real-Time Price · USD
2.050
-0.010 (-0.49%)
At close: May 18, 2026, 4:00 PM EDT
2.050
0.00 (0.00%)
After-hours: May 18, 2026, 4:10 PM EDT
Annovis Bio Employees
Annovis Bio had 7 employees as of December 31, 2025. The number of employees decreased by 8 or -53.33% compared to the previous year.
Employees
7
Change (1Y)
-8
Growth (1Y)
-53.33%
Revenue / Employee
n/a
Profits / Employee
-$5,846,216
Market Cap
71.03M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 7 | -8 | -53.33% | 7 | 0 |
| Dec 31, 2024 | 15 | -1 | -6.25% | 8 | 7 |
| Dec 31, 2023 | 16 | 11 | 220.00% | 6 | 10 |
| Dec 31, 2022 | 5 | 2 | 66.67% | 5 | 0 |
| Dec 31, 2021 | 3 | 1 | 50.00% | 3 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| XBiotech | 85 |
| Acrivon Therapeutics | 76 |
| Seres Therapeutics | 66 |
| PMV Pharmaceuticals | 54 |
| Pliant Therapeutics | 49 |
| Cue Biopharma | 29 |
| PDS Biotechnology | 24 |
| Gain Therapeutics | 21 |
ANVS News
- 3 days ago - Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 11 days ago - Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 - GlobeNewsWire
- 20 days ago - Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio - GlobeNewsWire
- 5 weeks ago - Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission - GlobeNewsWire
- 5 weeks ago - Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants - GlobeNewsWire
- 6 weeks ago - Annovis Bio secures U.S. patent for buntanetap - TheFly
- 6 weeks ago - Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections - GlobeNewsWire
- 6 weeks ago - Annovis Publishes Historical Review of Buntanetap in The Scientist - GlobeNewsWire